primary sclerosing cholangitis and primary biliary cirrhosis l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis PowerPoint Presentation
Download Presentation
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis

Loading in 2 Seconds...

play fullscreen
1 / 42

Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis - PowerPoint PPT Presentation


  • 500 Views
  • Uploaded on

Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis. Registrar teaching July 2007 Paul Frankish. Primary Biliary Cirrhosis PBC-introduction. Slowly progressive autoimmune liver disease 90% females Peak incidence in 40’s

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis' - albert


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
primary sclerosing cholangitis and primary biliary cirrhosis
Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis
  • Registrar teaching July 2007
  • Paul Frankish
primary biliary cirrhosis pbc introduction
Primary Biliary Cirrhosis PBC-introduction
  • Slowly progressive autoimmune liver disease
  • 90% females
  • Peak incidence in 40’s
  • Portal inflammation and autoimmune destruction of intrahepatic bile ducts
  • Leads to cirrhosis and liver failure
  • 90-95% have antimitochondrial antibody
clinical features
Clinical features
  • ~50% asymptomatic at diagnosis
  • Fatigue and pruritus most commonn symptoms~20%
  • Hyperlipidaemia,hypothyroidism,osteopenia,autoimmune diseases
  • Portal hypertension ,liver failure,HCC
physical examination
Physical examination
  • Often normal
  • Spiders and skin excoriations
  • Xanthelasmas
  • Hepatomegaly ~70%
  • Jaundice (late)
diagnosis
Diagnosis

3 criteria

Positive AMA

Abnormal LFT

Compatible biopsy

pathological stages 4
Pathological Stages (4)
  • 1 Destruction of bile ducts in portal tracts
  • 2 Inflammation beyond portal tracts
  • 3 fibrous septa link portal triads
  • Cirrhosis
epidemiology and genetic factors
Epidemiology and Genetic factors
  • Most prevalent in Nth Europe.10 fold variation
  • More common in first degree relatives
  • Molecular mimicry to certain bacteria or viruses
  • Environmental chemical exposure
autoimmune responses
Autoimmune responses
  • Targets of antimitichondrial antibodies
  • 4 autoreactive mitochondrial antigens
  • Pyruvate dehydrogenase E2 complex PDC-E2
  • E-3 binding protein E3-BP
  • Ketoglutaric acid dehydrogenase E2 complex OGDC-E2
  • 2 oxo-aciddehydrogenaseE-2 complex BCKD-E2
t cell response
T cell response
  • T cells infiltrating the liver are specific for PDC-E2
  • Nature of bile duct injury not fully elucidated
treatment ursodeoxycholic acid
Treatment:-Ursodeoxycholic acid

UDCA

Given in dose 12-15 mg/kg

Reduces bilirubin,ALP,AST,ALT cholesterol and IgM

Meta-analysis of 3 trials 548 patients UDCA reduced risk of liver transplantation or death over 4 years

Delays fibrosis and varices

Does not work in advanced disease

other drugs
Other drugs
  • Colchicine
  • Methotrexate
  • Budesoide
liver transplantation
Liver transplantation
  • Only effective Rx for liver failure
  • Survival is excellent 85% at 5 years
  • CAN RECUR IN GRAFT-30% AT 10 YEARS
definition

Definition

A chronic inflammatory cholestatic disease

Progressive destruction of bile ducts

May progress to cirrhosis

Aetiology unknown

epidemiology natural history and prognosis
Epidemiology,Natural History and Prognosis
  • Prevalence 6-8/100000
  • Usually diagnosed in 20s and 30s
  • Male predominance ~3:1
  • 80% have IBD –usually UC
  • ~44% asymptomatic at diagnosis
  • Median survival ~ 12 years
ibd and psc
IBD and PSC
  • Mainly associated with UC ~85%-the rest Crohns or indeterminate colitis
  • 4% UC patients will develop PSC
  • No correlation between activity of IBD and PSC
aetiology and pathogenesis
Aetiology and Pathogenesis
  • Familial incidence
  • HLA associations-B8,DR3,DRw52a,DR2,DR4
  • Polymorphism of TNF gene
immune factors
Immune factors
  • frequency autoimmune disorders
  • T cells in blood and liver
  • circulating immune complexes
autoantibodies
Autoantibodies
  • 95% patients with PSC have at least one autoantibody
  • 85% +ve ANCA
  • 50% +ve ANA
  • 25% +ve SMA
pathogenesis
Pathogenesis
  • Association between PSC and UC suggests a pathogenic interaction
  • ?bacteria or toxic substances absorbed via inflammed mucosa
  • Bile duct injury suggest ischaemic injury ?immune complex mediated
clinical manifestations
Clinical Manifestations
  • 44% asymptomatic but most develop symptoms over time
  • Pruritis,jaundice,pain and fatigue are common symptoms
  • Later on develop symptoms of cirrhosis and portal hypertension
cholangiocarcinoma
Cholangiocarcinoma
  • Lifetime prevalence of 10-30%
  • Annual risk 1.5% per year
  • Difficult to diagnose
  • Patients also have late risk of HCC
psc and bowel cancer
PSC and Bowel cancer
  • 25% PSC develop cancer or dysplasia cf 5.6% with UC alone
  • Cancers associated with PSC tend to be more proximal,are more advanced at diagnosis and mre likely to be fatal
  • Need aggressive colonoscopic surveillance
diagnosis27
Diagnosis
  • Cholangiography-either MRCP or ERCP
  • Clinical,biochemical and histological features
ercp and mrcp
ERCP and MRCP
  • Typical features:-

multifocal strictures and dilatation

usually affects both intra and

extrahepatic ducts

liver biopsy
Liver biopsy
  • Useful for staging disease
  • “Onion skin fibrosis” only in ~10% biopsies
  • ~5% patients have typical biopsy features with a normal cholangiogram
lab tests
Lab tests
  • LFTs-cholestatic pattern:ALP 3-5x ULN

-AST/ALT slightly elevated only

-raised bilirubin may occur with advanced disease,dominant stricture,cholangioca,stones,cholangitis

management
Management
  • Many strategies tried but only transplantation shown to improve survival
ursodeoxycholic acid
Ursodeoxycholic acid
  • Causes significant biochemical improvement
  • Little symptomatic or clinical benefit
  • May need high doses
  • Major role may be to reduce bowel cancer risk in patients with PSC/UC
  • Not funded in NZ !
steroids
Steroids
  • No long term data
  • Serious risk of bone disease
  • Colchicine, D-Penicillamine, Nicotine of no benefit
  • Combination Rx with UDCA Aza and steroids showed clinical and biochemical improvement in a small trial
endoscopic treatment
Endoscopic treatment
  • Direct injection of steroids into biliary tree ineffective
  • Balloon dilation or stenting can improve clinical,biochemical and cholangiographic appearances
  • Some reports of survival advantages and delay to liver transplantation
liver transplant
Liver Transplant
  • Only treatment to improve overall survival
  • Improves quality of life in 80% patients
  • 10 year survival post OLT ~70%
  • Aim to transplant before cholangica
  • Recurrent PSC in ~ 4% of grafts